An interventional study of butyrate/hexanoate-enriched triglycerides in Type 2 Diabetes, PreDiabetes and Obesity, sponsored by Maastricht University Medical Center. Completed at 1 site in Netherlands. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center — 2 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Maastricht University Medical Center.
Among the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center, this one is the 10th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2024, is one of 34 with no phase, and was the 38th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 40–75 · Healthy volunteers
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 31 across the 36 interventional studies, 72 across the 4 observational. Of the 33 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923644Maastricht University Medical CenterTargeted Precision Nutrition Strategy To Prevent Chronic Metabolic Diseases | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A body of animal studies as well as observational studies in humans demonstrated that butyrate is one SCFA that has pronounced positive effects on body weight control, inflammation, and insulin resistance. Even though the SCFA hexanoate is less researched, it has been shown to be involved in anti-inflammatory processes. Of note, acute human studies showed that fibre-induced metabolic improvements are linked to higher SCFA levels in the systemic circulation. It has been shown that a butyrate/hexanoate-enriched triglyceride oil enhanced systemic butyrate and hexanoate concentrations for a prolonged time. Yet, it remains to be determined whether a chronic increase in circulating butyrate and hexanoate concentrations translate into long-term benefits. In this study it is hypothesized that a chronic increase of butyrate/hexanoate in the circulation may improve host metabolism and metabolic health by improving adipose tissue function, reducing systemic lipid overflow and inflammation thereby increasing peripheral insulin sensitivity in individual with overweight/obesity and prediabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
One or more of the following criteria to determine disturbed glucose/insulin homeostasis
Exclusion Criteria:
Diabetes mellitus (type 1 or 2)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oil containing butyrate and hexanoate-enriched triglycerides
Dietary Supplement: butyrate/hexanoate-enriched triglycerides
Oil devoid of butyrate and hexanoate but with similar composition as the intervention oil
Dietary Supplement: butyrate/hexanoate-enriched triglycerides
The oils are consumed two times a day for 24 weeks (six months).
Peripheral insulin sensitivity
The change of peripheral insulin sensitivity as assessed by a hyperinsulinaemic-euglycemic clamp
Time frame: Before and 6 months after the start of the intervention
hepatic insulin sensitivity
The change in hepatic insulin sensitivity as assessed by a hyperinsulinaemic-euglycemic clamp
Time frame: Before and 6 months after the start of the intervention
adipose tissue insulin sensitivity
The change in adipose tissue insulin sensitivity as assessed by a hyperinsulinaemic-euglycemic clamp
Time frame: Before and 6 months after the start of the intervention
Energy expenditure (indirect calorimetry)
The change in energy expenditure as measured via ventilated hood system
Time frame: Before and 6 months after the start of the intervention
Substrate oxidation (indirect calorimetry)
The change in substrate oxidation as measured via ventilated hood system
Time frame: Before and 6 months after the start of the intervention
circulating SCFA
The change in concentrations of circulating SCFA
Time frame: Before and 6 months after the start of the intervention
Faecal SCFA
The change in concentrations of faecal SCFA
Time frame: Before and 6 months after the start of the intervention
Faecal microbiota composition
The change in faecal microbiota composition assessing abundances of bacteria and diversity indices as assessed via 16s rRNA gene
Time frame: Before and 6 months after the start of the intervention
Circulating hormones such as insulin
The change in concentrations of circulating hormones in peripheral blood
Time frame: Before and 6 months after the start of the intervention
Circulating metabolites such as glucose
The change in concentrations of metabolites in peripheral blood
Time frame: Before and 6 months after the start of the intervention
body composition
The change in body composition as assessed using DEXA scans
Time frame: Before and 6 months after the start of the intervention
body weight
The change in body weight in kg using a weight scale
Time frame: Before and 6 months after the start of the intervention
Gut permeability
The change in gut permeability as assessed using a multi-sugar test
Time frame: Before and 6 months after the start of the intervention
Ran from Sep 2024 to primary completion in Sep 2026, 24 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 24 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Sep 2027 → Sep 2026 and completion Sep 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →